Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa

被引：49
|
作者：
Poirel, Laurent [1 ,3 ,4 ]
de la Rosa, Jose-Manuel Ortiz [1 ]
Sadek, Mustafa [1 ,2 ]
Nordmann, Patrice [1 ,3 ,4 ,5 ,6 ]
机构：
[1] Univ Fribourg, Fac Sci & Med, Med & Mol Microbiol, Fribourg, Switzerland
[2] South Valley Univ, Fac Vet Med, Dept Food Hyg & Control, Qena, Egypt
[3] Univ Fribourg, INSERM European Unit IAME, Fribourg, Switzerland
[4] Univ Fribourg, Swiss Natl Reference Ctr Emerging Antibiot Resist, Fribourg, Switzerland
[5] Univ Lausanne, Inst Microbiol, Lausanne, Switzerland
[6] Univ Hosp Ctr, Lausanne, Switzerland
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2022年 / 66卷 / 04期
基金：
瑞士国家科学基金会;
关键词：
cefiderocol; Pseudomonas aeruginosa; susceptibility testing; beta-lactamase; RESISTANCE;
D O I：
10.1128/aac.00039-22
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The ability of broad-spectrum beta-lactamases to reduce the susceptibility to ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam (AZA), and cefiderocol (FDC) was evaluated both in Pseudomonas aeruginosa and in Escherichia coli using isogenic backgrounds. Although metallo-beta-lactamases conferred resistance in most cases, except for AZA, several clavulanic-acid-inhibited extended-spectrum beta-lactamases (PER, BEL, SHV) had a significant impact on the susceptibility to CZA, C/T, and FDC.
引用
收藏
页数：6
相关论文
共 20 条
  • [1] Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa
    Le Terrier, Christophe
    Nordmann, Patrice
    Freret, Charlotte
    Seigneur, Marion
    Poirel, Laurent
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (07)
  • [2] Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa
    Gonzalez-Pinto, Lucia
    Alonso-Garcia, Isaac
    Blanco-Martin, Tania
    Camacho-Zamora, Pablo
    Fraile-Ribot, Pablo Arturo
    Outeda-Garcia, Michelle
    Lasarte-Monterrubio, Cristina
    Guijarro-Sanchez, Paula
    Maceiras, Romina
    Moya, Bartolome
    Juan, Carlos
    Vazquez-Ucha, Juan Carlos
    Beceiro, Alejandro
    Oliver, Antonio
    Bou, German
    Arca-Suarez, Jorge
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (10) : 2591 - 2597
  • [3] Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa
    Le Terrier, Christophe
    Freire, Samanta
    Viguier, Clement
    Findlay, Jacqueline
    Nordmann, Patrice
    Poirel, Laurent
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024,
  • [4] Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in Enterobacterales
    Sadek, Mustafa
    Duran, Juan Bosch
    Poirel, Laurent
    Nordmann, Patrice
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (05)
  • [5] Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli
    Le Terrier, Christophe
    Nordmann, Patrice
    Bouvier, Maxime
    Poirel, Laurent
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (10)
  • [6] Activity of cefiderocol and innovative β-lactam/ β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions (vol 63, 107150, 2024)
    Blanco-Martin, Tania
    Alonso-Garcia, Isaac
    Gonzalez-Pinto, Lucia
    Outeda-Garcia, Michelle
    Guijarro-Sanchez, Paula
    Lopez-Hernandez, Inmaculada
    Perez-Vazquez, Maria
    Aracil, Belen
    Lopez-Cerero, Lorena
    Fraile-Ribot, Pablo
    Oliver, Antonio
    Vazquez-Ucha, Juan Carlos
    Beceiro, Alejandro
    Bou, German
    Arca-Suarez, Jorge
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 64 (02)
  • [7] Reclaiming the Efficacy of β-Lactam-β-Lactamase Inhibitor Combinations: Avibactam Restores the Susceptibility of CMY-2-Producing Escherichia coli to Ceftazidime
    Papp-Wallace, Krisztina M.
    Winkler, Marisa L.
    Gatta, Julian A.
    Taracila, Magdalena A.
    Chilakala, Sujatha
    Xu, Yan
    Johnson, J. Kristie
    Bonomo, Robert A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) : 4290 - 4297
  • [8] VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
    Hamrick, Jodie C.
    Docquier, Jean-Denis
    Uehara, Tsuyoshi
    Myers, Cullen L.
    Six, David A.
    Chatwin, Cassandra L.
    John, Kaitlyn J.
    Vernacchio, Salvador F.
    Cusick, Susan M.
    Trout, Robert E. L.
    Pozzi, Cecilia
    De Luca, Filomena
    Benvenuti, Manuela
    Mangani, Stefano
    Liu, Bin
    Jackson, Randy W.
    Moeck, Greg
    Xerri, Luigi
    Burns, Christopher J.
    Pevear, Daniel C.
    Daigle, Denis M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [9] Activity of cefiderocol and innovative fi-lactam/ fi-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double fi-lactamases under high and low permeability conditions
    Blanco-Martin, Tania
    Alonso-Garcia, Isaac
    Gonzalez-Pinto, Lucia
    Outeda-Garcia, Michelle
    Guijarro-Sanchez, Paula
    Lopez-Hernandez, Inmaculada
    Perez-Vazquez, Maria
    Lopez-Cerero, Lorena
    Fraile-Ribot, Pablo
    Oliver, Antonio
    Vazquez-Ucha, Juan Carlos
    Beceiro, Alejandro
    Bou, German
    Arca-Suarez, Jorge
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (05)
  • [10] β-Lactam/β-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
    Rodriguez-Bano, Jesus
    Navarro, Maria Dolores
    Retamar, Pilar
    Picon, Encarnacion
    Pascual, Alvaro
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 54 (02) : 167 - 174
12